5月8日，科伦药业（002422.SZ）董事长刘革新以一则"赤膊上阵"代言产品的视频冲上热搜。5月14日， 刘革新通过公开信正式回应，宣布将抗衰老赛道作为继大输液、抗生素、创新药之后的"第四次创业"， 称其目标是"共建抗衰老事业的生态平台"。 政策层面看，我国积极应对人口老龄化国家战略深入推进，"健康中国2030"规划纲要明确将"提高人民 健康水平"作为核心。业内人士指出，这一政策导向为大健康产业注入强劲动力，抗衰老领域成为政策 红利的直接受益者。 为此，科伦药业在2024年11月投资设立科伦永年，负责麦角硫因等大健康产品的销售。 健身与产品的协同效应 公开资料显示，刘革新代言的产品"麦角硫因"于2022年11月1日首次出现在科伦药业的公告中。根据公 司公告，该产品由上海川宁药物研究院独立研发，工艺包成熟后，交付给科伦药业子公司川宁生物实现 商业化。 来源：科伦集团微信视频号 银发经济崛起叠加政策红利 当前，随着大众健康需求的不断增长和银发经济规模的不断扩大，抗衰老研究已成为国际生物医学领域 的前沿热点。国家统计局数据显示，截至2024年末，我国60岁及以上人口达到3.1亿人，首次突破3亿 人。老龄化加剧叠加 ...

Market Overview - On May 15, the three major stock indices in Shanghai and Shenzhen opened lower and experienced fluctuations, with the ChiNext index leading the decline [1] - The Shanghai Composite Index closed at 3389.75 points, down 0.42%, with a trading volume of approximately 293.5 billion yuan; the Shenzhen Component Index closed at 10238.63 points, down 1.12%, with a trading volume of approximately 446.9 billion yuan; the ChiNext Index closed at 2055.06 points, down 1.35%, with a trading volume of approximately 206.2 billion yuan [1] Sector Performance - The consumer sector showed strength, with significant gains in beauty care, pet economy, and food sectors, including stocks like Jieya Co., Lafang Home, and Xiwang Food hitting the daily limit [1] - The synthetic biology concept also surged, with stocks like Chuaning Biology, Furida, and Jindawei reaching the daily limit [1] - Conversely, computing power concept stocks underwent adjustments, with Hongjing Technology dropping nearly 10% [1] Institutional Insights - Galaxy Securities noted that the temporary easing of tariff policies benefits electronic companies exporting directly to the U.S., reducing costs associated with transshipment trade, and provides a window for domestic consumer electronics companies [3] - Huatai Securities highlighted the CIBF2025 event focusing on solid-state batteries and related technologies, indicating a strong interest in the solid-state battery sector [3] - Changjiang Securities emphasized that stable fundamentals, high dividend logic, and the expansion of passive funds will drive the continued recovery of undervalued bank stocks [3] News Highlights - China led the development of international standards for an aging-inclusive digital economy, with the ISO publishing guidelines that address the participation of the elderly in various digital economic scenarios [4] - Sensor Tower reported that global in-app purchase revenue for short video applications reached nearly $700 million in Q1 2025, nearly quadrupling from Q1 2024, with the U.S. being the highest revenue market [5] - Heng Rui Medicine officially launched a global public offering of H-shares, planning to issue 225 million shares, with a potential maximum fundraising amount of 13.08 billion HKD [6]

Market Overview - The market experienced fluctuations in the morning session, with the ChiNext Index leading the decline, down 1.35% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 740.4 billion, an increase of 23.6 billion compared to the previous trading day [1] - Overall, more than 3,600 stocks declined across the market, indicating a broad-based sell-off [1] Sector Performance - Synthetic biology stocks surged against the trend, with companies like Jindawei hitting the daily limit [1] - Port and shipping stocks maintained strong performance, with Nanjing Port also reaching the daily limit [1] - The ST (Special Treatment) sector showed renewed strength, with over 20 stocks, including ST Huapeng, hitting the daily limit [1] - Conversely, computing power concept stocks underwent adjustments, with Hongjing Technology dropping nearly 10% [1] Index Performance - By the end of the session, the Shanghai Composite Index fell by 0.42%, the Shenzhen Component Index decreased by 1.12%, and the ChiNext Index dropped by 1.35% [1]

Market Overview - The three major A-share indices collectively declined in the morning session, with the Shanghai Composite Index down by 0.42%, the Shenzhen Component Index down by 1.12%, and the ChiNext Index down by 1.35% [1] - The North China 50 Index, however, saw an increase of 0.55% [1] - The total market turnover reached 765.6 billion yuan, an increase of 30 billion yuan compared to the previous day [1] - Over 3,600 stocks in the market experienced declines [1] Sector Performance - The beauty care, pet economy, port shipping, and chemical fiber sectors led the gains [1] - Conversely, the Huawei Ascend, cloud computing, and cross-border payment sectors experienced the largest declines [1] Notable Stocks - The port shipping sector saw a resurgence, with stocks such as Nanjing Port, Lianyungang, Ningbo Shipping, and Ningbo Ocean achieving three consecutive trading limits [1] - The beauty care sector also performed well, with Jieya Co., Ltd. hitting the daily limit up of 20% [1] - In contrast, stocks related to Huawei Ascend and cloud computing, such as Hongjing Technology, saw a decline of nearly 10% [1]

Core Viewpoint - 恒兴新材 is navigating a challenging market environment while focusing on growth opportunities in high-quality specialty chemicals and synthetic biology [1][2]. Group 1: Financial Performance - In 2024, 恒兴新材's overall product sales reached 65,000 tons, an increase of 30.15% year-on-year [1]. - The company's revenue surpassed 700 million yuan for the first time, marking a year-on-year growth of 13.37% [1]. - The net cash flow from operating activities was 36.3 million yuan, reflecting a year-on-year increase of 10.56% [1]. - The company's EBITDA reached 103 million yuan [1]. Group 2: Strategic Initiatives - In the first quarter of 2025, 恒兴新材 experienced significant growth in operating performance due to increased sales efforts and market expansion [2]. - The company has made strategic investments in the synthetic biology sector, partnering with 依诺基科 to leverage its technological advantages and enhance product offerings [2]. - The focus on green bio-manufacturing aims to meet market demands for environmentally friendly and health-oriented products [2]. Group 3: Agricultural Sector Focus - 恒兴新材 is committed to optimizing and upgrading its pesticide intermediates to support the performance and environmental standards of downstream agricultural producers [3]. - The company plans to explore new business models and opportunities by establishing strategic partnerships with pesticide formulation companies [3].

Group 1: Financial Performance - In 2024, the pharmaceutical industrial revenue reached CNY 672 million, with gross margins for formulations and APIs at 61.25% and 20.24% respectively [1] - The revenue from traditional Chinese medicine (TCM) slices was CNY 260 million, holding a market share of 23.1% in Zhejiang Province [2] - The retail pharmaceutical business generated CNY 1.239 billion, reflecting a year-on-year growth of 8.04% [2] - The company reported a gross margin of 18.81%, an increase of 0.13 percentage points, while the net profit margin decreased by 1.10 percentage points [4] Group 2: Research and Development - In 2024, R&D investment amounted to CNY 55.6334 million, a year-on-year increase of 20.53% [1] - The R&D focus includes technologies for histidine, L-DOPA, and L-tyrosine production via fermentation, with the Xiaoshan industrial base expected to commence trial production in Q3 2024 [2] Group 3: Market Strategy and Expansion - The top five customers contributed 11.14%-13.71% of total revenue, indicating a reliance on local hospitals [1] - The company aims to reduce dependency on regional medical institutions by collaborating with China Resources for strategic market expansion [1] - The company plans to enhance its national market share through a three-step strategy focusing on quality improvement and international standards in TCM [2] Group 4: Operational Challenges - The pharmaceutical wholesale business saw a revenue decline of 17.97% due to slow hospital payments, leading to increased accounts receivable and credit impairment losses [4] - Management expenses rose by 20.04%, primarily due to increased personnel costs and operational expenses related to the Xiaoshan project [2] Group 5: Future Outlook - The synthetic biology project is expected to achieve 100% capacity utilization three years post-production [4] - The company is actively exploring opportunities in the central and western markets, considering mergers or partnerships for accelerated growth [6] - The introduction of China Resources as a strategic investor is anticipated to enhance supply chain management and operational efficiency [5]

Core Viewpoint - Jiangsu Hengxing New Materials Technology Co., Ltd. held an earnings briefing on May 13, 2025, to discuss its performance for the fiscal year 2024 and the first quarter of 2025, engaging with investors on various operational and financial aspects [1][2]. Earnings Briefing Overview - The earnings briefing was conducted via the Shanghai Stock Exchange's online platform, allowing for interactive communication between the company's management and investors [1][2]. - Key executives present included Chairman Zhang Qian, General Manager Wang Hengxiu, and Financial Director Zhou Hongyun, who addressed investor inquiries within the scope of information disclosure [2]. Key Investor Questions and Responses - **Strategic Layout in Synthetic Biology**: The company has made strategic investments in the synthetic biology sector, collaborating with Yinuo Technology to enhance its competitive edge in green biological manufacturing and expand its product lines [2][3]. - **Agricultural Sector Operations**: The company is focused on optimizing its pesticide intermediates and exploring new business models in the agricultural supply chain to promote green agricultural development [2][3]. - **Dividend Distribution**: The company plans to distribute a cash dividend of 0.125 yuan per share, with a payout ratio of 73.69%, reaffirming its commitment to returning value to shareholders [2][3]. - **First Quarter Performance Growth**: The significant growth in the first quarter of 2025 is attributed to increased sales efforts, market expansion, and stable supply chain management, leading to a rapid increase in product sales [3][4]. - **Future Dividend Plans**: The company aims to maintain a cash dividend ratio of 73.69% of the annual net profit attributable to shareholders, adhering to relevant regulations and its dividend policy [3][4]. - **Technological Advantages and Market Performance**: The company emphasizes innovation and has strengthened its R&D capabilities, focusing on developing new products and processes to enhance production efficiency and sustainability [4][5]. Industry Policy Environment - The company operates in the fine chemicals and new materials sector, benefiting from favorable government policies aimed at promoting high-end, green, and digital transformation within the industry [5][6]. - The industry is moving towards high-end, green, intelligent, differentiated, and safe production, with a focus on enhancing competitiveness and achieving sustainable growth [6].

Core Insights - Shenzhen has introduced new legislation aimed at promoting the innovation and development of the synthetic biology industry, addressing key challenges such as supply chain coordination and long approval cycles for new materials [1][5]. Group 1: Legislative Developments - The draft regulations consist of 30 articles and aim to tackle common pain points in the synthetic biology industry, including supply chain issues and the lengthy approval process for new materials [1]. - The regulations will be open for public consultation until June 13, indicating a collaborative approach to policy-making [1]. Group 2: Market Potential - According to McKinsey, the global bioeconomy is projected to reach $2 trillion to $4 trillion in the next 10-20 years, with the contribution of biological modification expected to rise to 30%-70% over time [1][4]. - In China, 40% of newly established synthetic biology companies in the past three years are concentrated in Shenzhen, highlighting the city's growing significance in this sector [1][5]. Group 3: Industry Collaboration - The draft regulations emphasize collaboration with national and provincial health departments to enhance the safety assessment of new food materials and additives [3]. - The regulations also aim to improve the efficiency of the approval process for new cosmetic ingredients, addressing existing challenges such as high costs and long timelines [2][3]. Group 4: Support Mechanisms - Shenzhen plans to establish specialized industrial parks for synthetic biology, providing necessary R&D and production facilities, as well as public technical services [5][6]. - The city will support higher education institutions in offering programs related to synthetic biology and encourage partnerships between academia and industry to cultivate talent [5][6]. Group 5: Financial Initiatives - The Shenzhen government will leverage investment funds to support small and medium-sized enterprises in the synthetic biology sector, enhancing access to financing for startups [6]. - A private equity fund focused on synthetic biology was established in Shenzhen with a scale of 1.5 billion yuan, and local banks have increased credit limits for startups in this field [6].

Core Viewpoint - The article highlights the launch of a specialized production line for high-end bioactive molecules by KaiXing Bio, marking a significant advancement in the synthetic biology industry in China [1][3]. Group 1: Company Overview - KaiXing Bio, established in May 2024, is a subsidiary of Beijing Green Kangcheng Biotechnology Co., Ltd., stemming from decades of research by Tsinghua University in the biotechnology field [1]. - The company focuses on next-generation biotechnology to create an intelligent manufacturing platform for the green production of high-end chemicals, providing sustainable bioactive raw material solutions for the global market [3]. Group 2: Production and Products - The newly launched factory in Changzhou will mass-produce high-value amino acids and bioactive raw materials, including N-acetylneuraminic acid, L-histidine, carnosine, decarboxylated carnosine, ergothioneine, rhodiola rosea glycosides, and ectoine, which are widely used in dietary supplements, functional skincare, and biomedicine [4]. - KaiXing Bio released the first batch of synthetic biological product standards in Jiangsu Province during the launch ceremony, setting a new quality benchmark for Chinese raw materials [5]. Group 3: Industry Impact and Future Plans - The combination of "raw materials + standards" aims to enhance the domestic substitution and standard system construction in the synthetic biology field, injecting strong momentum into the industry [7]. - The company plans to strengthen industry chain cooperation, promote green and sustainable biomanufacturing technology innovation, and continuously provide high-quality, environmentally friendly, and efficient bioactive raw material solutions to global customers [7]. - KaiXing Bio aims to expand its product matrix and accelerate its global market layout, promoting the concepts of health, beauty, and sustainability, while leading the active raw material industry with "Made in China" initiatives [7].

Group 1: Company Performance and Market Outlook - The company has no current plans for share reduction despite market fluctuations [2] - The domestic market for G-CSF reached nearly 10 billion RMB in 2022, indicating significant demand [9] - The company expects to ship approximately 40,000 units of overseas orders in 2025, including shipments to the U.S. market [3] Group 2: Product Development and Clinical Trials - F-652 is undergoing clinical trials with a focus on alcohol-related liver disease, with ongoing internal strategy discussions to mitigate risks [22] - The F-627 product is expected to launch in the U.S. around June 2025, with a projected shipment of 270,000 units [17] - The company anticipates that the new cell toxic production line in Hefei will be completed as scheduled [2] Group 3: Investor Relations and Communication - Investors expressed concerns about the company's communication effectiveness, particularly regarding the management's responsiveness to shareholder inquiries [5] - The company acknowledges the need for improved investor relations and plans to enhance communication strategies [21] - The management is committed to ensuring that the stock price reflects the company's true value and will work on investor engagement [21] Group 4: Financial Management and Market Strategy - The company reported a 13.55% decrease in net profit due to lower gross margins from synthetic biological products and the impact of centralized procurement [20] - The company is focusing on maintaining competitive pricing and expanding market share in the vitamin B5 sector despite current price pressures [20] - The company plans to leverage its strengths in quality and production capacity to sustain its market leadership in the vitamin sector [20]